International journal of hematology-oncology and stem cell research最新文献_第3页

MDS-Type Morphologic Abnormalities of Peripheral Blood Granulocytes in Symptomatic COVID-19 Patients 有症状的 COVID-19 患者外周血粒细胞的 MDS 型形态异常

International journal of hematology-oncology and stem cell research Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16105

Mohammad Jafar Sharifi, Negar Gheibi, Fatemeh Panahi, S. Sharifzadeh, N. Nasiri

{"title":"MDS-Type Morphologic Abnormalities of Peripheral Blood Granulocytes in Symptomatic COVID-19 Patients","authors":"Mohammad Jafar Sharifi, Negar Gheibi, Fatemeh Panahi, S. Sharifzadeh, N. Nasiri","doi":"10.18502/ijhoscr.v18i3.16105","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16105","url":null,"abstract":"Background: Hematological abnormalities in COVID-19 infection included quantitative and qualitative changes and should be further characterized. Evaluation for myelodysplastic syndromes (MDS) is usually prompted by abnormal hematologic findings and the presence of dysplastic morphologies. Viral infections are considered to be the cause of dysplastic morphologies and should be considered by morphologists. There are few reports of dysplastic abnormal morphologies in patients with COVID-19 infection. However, such correlations still have to be clarified. \u0000Materials and Methods: In the present study, we examined the granulocyte lineage morphological abnormalities in symptomatic RT-PCR-confirmed COVID patients. Peripheral blood samples were collected from 82 patients with symptomatic COVID-19. Blood smears were prepared according to the standard Wright-Giemsa staining procedure. The morphological examination was carried out by two laboratory experts. \u0000Results: Blood smear examination revealed common myelodysplastic syndrome (MDS) type abnormalities including but not limited to pseudo-pelger nuclear lobulation (4.8%), hypogranulation (7.3%), Howell-Jolly-like bodies or detached nuclear segments (6.0%) and elongated and thin nuclear filaments (6.0%). One case of abnormal immature granulocyte and ring form nucleus is also evident. \u0000Conclusion: Our results accounted for the possibility of active COVID-19 infection in all subjects with granulocyte dysplasia. These results are of practical importance for patients suspected of having myelodysplastic syndromes or disease processes associated with myeloid malignancies.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"44 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after “Allogeneic Stem Cell Transplantation from 9/10HLA Matched Unrelated Donor’’ with Standard Graft Versus Host Disease Prophylaxis after “10/10HLA Matched Relative Donor’’ 基于环磷酰胺的 "9/10HLA 匹配非亲缘供体异体干细胞移植 "后移植物抗宿主疾病预防疗法与 "10/10HLA 匹配亲缘供体 "后标准移植物抗宿主疾病预防疗法的比较

International journal of hematology-oncology and stem cell research Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16103

Murat Yıldırım, S. Sayın, Melda Cömert, Esra Safak Yilmaz, F. Avcu, A. Ural, M. Aylı

{"title":"Comparison of Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis after “Allogeneic Stem Cell Transplantation from 9/10HLA Matched Unrelated Donor’’ with Standard Graft Versus Host Disease Prophylaxis after “10/10HLA Matched Relative Donor’’","authors":"Murat Yıldırım, S. Sayın, Melda Cömert, Esra Safak Yilmaz, F. Avcu, A. Ural, M. Aylı","doi":"10.18502/ijhoscr.v18i3.16103","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16103","url":null,"abstract":" \u0000Background: Graft Versus Host Disease (GvHD), which can be observed at a rate of 30-80% after allogeneic stem cell transplantation (ASCT) is an important complication that adversely affects the survival and quality of the life of patients. Posttransplant cyclophosphamide (PTCy) effectively prevents GvHD after HLA-haploidentical ASCT. In our study, the use of PTCy in 1-antigen HLA-mismatched unrelated donor (9/10MMUD) ASCT was compared with standard GvHD prophylaxis in HLA-identical related donor (MRD) ASCT. \u0000Materials and Methods: We conducted a retrospective study of the comparison of 42 patients with 9/10 MMUD ASCT receiving PTCy+Methotrexate (MTX)+Calcineurin Inhibitor (CNI) and 37 patients with HLA-identical MRD who received MTX+CNI in 3 bone marrow transplantation centers. \u0000Results: Cumulative incidences of grade I-II (64.6% vs 45.4%, p=0.187) or grade III to IV acute GvHD (35.4% vs54.6%, p=0.187) and chronic GvHD (11.9% vs 29.7%, p=0.096) were similar in the PTCy group and control group. No statistically significant differences were observed between PTCy and the control group in overall survival rate (52.4% vs 62.2%, p=0.381), progression-free survival (1483.97 vs 1200.70 days, p=0.502), relapsed-related mortality rate (21.4% vs 16.2%, p=0.556) and treatment-related mortality rate (16.7% vs 21.6%, p=0.575). \u0000Conclusion: With the addition of PTCy to standard GvHD prophylaxis in 9/10MMUD ASCT, the risk of GvHD due to incompatibility and unrelated transplantation is eliminated, and transplantation success is achieved with MRD ASCT. PTCy-based prophylaxis is an effective and safe strategy to prevent GvHD in 9/10 MMUD ASCT without increasing the risk of relapse and treatment-related mortality.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"100 40","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Relationship between the Lifestyle of the Allogeneic Stem Cell Donors and the Number of Donated CD34+ and CD3+ Cells 异体干细胞捐献者的生活方式与捐献的 CD34+ 和 CD3+ 细胞数量之间的关系

International journal of hematology-oncology and stem cell research Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16101

Leila Sayadi, Saeed Mohammadi, Parivash Aminian

{"title":"The Relationship between the Lifestyle of the Allogeneic Stem Cell Donors and the Number of Donated CD34+ and CD3+ Cells","authors":"Leila Sayadi, Saeed Mohammadi, Parivash Aminian","doi":"10.18502/ijhoscr.v18i3.16101","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16101","url":null,"abstract":"Background: Hematopoietic stem cell transplantation (HSCT) is considered as the last treatment option in many life-threatening diseases. The number of donated cells can affect transplantation success. This study attempted to investigate the relationship between the health-promoting lifestyle of allogeneic stem cell donors and the number of donated CD34+ and CD3+ cells. \u0000Materials and Methods: The study was a descriptive correlational study in which 100 peripheral blood stem cells donors participated. A demographic form and health-promoting lifestyle profile-II questionnaire were distributed to participants, and then cell separation was started. Afterward, the results of CD34 + and CD3 + cell counts, as well as other clinical parameters of the participants, were recorded. The collected data were analyzed by descriptive and analytical statistical methods. \u0000Results: The results showed that the mean total health-promoting lifestyle profile score for hematopoietic stem cell donors was 2.876±0.461. There was no significant relationship between the health- promoting lifestyle score and the number of CD34+, CD3+ cells and CD3+/CD34+ ratio. A positive and significant correlation was found between the weight of the donors and the number of CD34+ (P < 0.001) and CD3+ cells (P = 0.001). The number of CD34+ cells was significantly different between women and men (P = 0.009). \u0000Conclusion: Lifestyle had no significant effect on the number of CD3+/CD34+ cells. Moreover, the number of CD34+ cells was significantly higher in men, so males should be preferentially recruited as donors for the HSCT procedure.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"82 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141819239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and Paraclinical Features, Outcome, and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study of 31 Vietnamese Patients 鼻型结节外天然杀伤/T细胞淋巴瘤的临床和辅助临床特征、结果和预后：对 31 名越南患者的回顾性研究

International journal of hematology-oncology and stem cell research Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16107

Kien Hung Do, Tu Anh Do, Tai Van Nguyen, Duc Thanh Le, Linh Van Phan, C. Nguyen

{"title":"Clinical and Paraclinical Features, Outcome, and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study of 31 Vietnamese Patients","authors":"Kien Hung Do, Tu Anh Do, Tai Van Nguyen, Duc Thanh Le, Linh Van Phan, C. Nguyen","doi":"10.18502/ijhoscr.v18i3.16107","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16107","url":null,"abstract":"Background: Extranodal natural killer (NK)/T-cell lymphoma, nasal type is a rare, aggressive, and poor prognostic subtype. The concurrent chemoradiotherapy followed by chemotherapy showed a relatively high response rate and the toxicity due to the treatment is acceptable. The study attempted to report the clinicopathological features, the survival outcome, and response rates of stages I-II, nasal type ENKTL patients treated with CCRT followed by adjuvant VIPD chemotherapy in Vietnam. \u0000Materials and Methods: The current study was conducted on 31 stage I or II NK/T cell lymphoma, nasal-type patients received by CCRT, followed by adjuvant VIPD chemotherapy. Information on patient demographics, disease stage, clinical symptoms, tumor, and paraclinical characteristics were collected. The primary endpoints of this study were OS and response rates. \u0000Results: After CCRT, 26 out of 31 (83.9%) patients had stable disease or response. Overall response rate (ORR) was observed in 80.6% of patients with a complete response rate of 67.7%. Low-risk PINK patients had a higher response rate than the intermediate- risk group (p=0.038). Mean disease-free survival was 44.3±4.5 months (95% CI, 35.4-53.1 months). Mean overall survival was 46.8±4.5 months (95% CI, 37.99-55.8 months). The intermediate-risk PINK patients had a significantly lower OS rate than low-risk patients. \u0000Conclusion: Concurrent chemoradiotherapy followed by adjuvant VIPD chemotherapy showed a high response rate and survival benefit in stages I-II, nasal type, and extranodal natural killer (NK)/T-cell lymphoma Vietnamese patients.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"09 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Silibinin, Synergistically Enhances Vinblastine-Mediated Apoptosis in Triple Negative Breast Cancer Cell Line: Involvement of Bcl2/Bax and Caspase-3 Pathway Silibinin, Synergistically Enhances Vinblastine-Mediated Apoptosis in Triple Negative Breaster Cancer Cell Line：Bcl2/Bax 和 Caspase-3 通路的参与

International journal of hematology-oncology and stem cell research Pub Date : 2024-04-24 DOI: 10.18502/ijhoscr.v18i2.15375

H. Dariushnejad, Neda Roshanravan, Hunar Mustafa Wasman, Mostafa Cheraghi, Lale Pirzeh, V. Ghorbanzadeh

{"title":"Silibinin, Synergistically Enhances Vinblastine-Mediated Apoptosis in Triple Negative Breast Cancer Cell Line: Involvement of Bcl2/Bax and Caspase-3 Pathway","authors":"H. Dariushnejad, Neda Roshanravan, Hunar Mustafa Wasman, Mostafa Cheraghi, Lale Pirzeh, V. Ghorbanzadeh","doi":"10.18502/ijhoscr.v18i2.15375","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i2.15375","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) with a poor prognosis and survival is the most invasive subtype of breast cancer. Usually, TNBC requires a chemotherapy regimen at all stages, but chemotherapy drugs have shown many side effects. We assumed that combination therapy of vinblastine and silibinin might reduce the vinblastine toxicity and dose of vinblastine. \u0000Materials and Methods: The MDA-MB-231 were cells subjected to MTT assay for IC50 determination and combination effects, which were measured based on Chou-Talalay's method. The type of cell death was determined by using a Flow-cytometric assay. Cell death pathway markers, including Bcl-2, Bax, and caspase-3 were analyzed by western blot and Real-Time PCR. \u0000Results: The treatment of MDA-MB-231 cells exhibited IC50 and synergism at the combination of 30 µM of silibinin and 4 µm of vinblastine in cell viability assay (CI=0.69). YO-PRO-1/PI double staining results showed a significant induction of apoptosis when MDA-MB-231 cells were treated with a silibinin and vinblastine combination (p<0.01). Protein levels of Bax and cleaved caspase-3 were significantly upregulated, and Bcl-2 downregulated significantly. Significant upregulation of Bax (2.96-fold) and caspase-3 (3.46-fold) while Bcl-2 was downregulated by 2-fold. \u0000Conclusion: Findings established a preclinical rationale for the combination of silibinin and vinblastine. This combination produces synergistic effects in MDA-MB-231 cells by altering pro- and anti-apoptotic genes, which may reduce the toxicity and side effects of vinblastine.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"66 51","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140664159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Deep Venous Thrombosis in an HIV-Infected Patient despite Therapeutic Anticoagulation 一例艾滋病毒感染者在接受抗凝治疗后仍出现深静脉血栓的病例

International journal of hematology-oncology and stem cell research Pub Date : 2024-04-24 DOI: 10.18502/ijhoscr.v18i2.15379

Wajeeha Aiman, Muhammad Ashar Ali, Navjot Grewal, Andreas A. Savopoulos, G. Guron

引用次数: 0

HHV-8 Linked to Kaposi's Sarcoma and Castleman's Disease in HIV-1-infected patient: Case Report and Review of the Literature HHV-8 与 HIV-1 感染者的卡波西肉瘤和 Castleman 病有关：病例报告与文献综述

International journal of hematology-oncology and stem cell research Pub Date : 2024-04-24 DOI: 10.18502/ijhoscr.v18i2.15378

A. Zaghdoudi, Hajer Harrabi, Hanene Tiouiri Benaissa

引用次数: 0

Hemoglobin C Disorder in Anemic Patients Referred to the National Center for Thalassemia and Genetic Counseling in Damascus 大马士革国家地中海贫血症和遗传咨询中心转诊的贫血患者中的血红蛋白 C 紊乱症

International journal of hematology-oncology and stem cell research Pub Date : 2024-04-24 DOI: 10.18502/ijhoscr.v18i2.15376

Aya Ahmad, Karam Fattoum, Wael Imam, Mhd Yasser Mukhalalaty, Musab Murad, Faizah Ali Al Quobaili

{"title":"Hemoglobin C Disorder in Anemic Patients Referred to the National Center for Thalassemia and Genetic Counseling in Damascus","authors":"Aya Ahmad, Karam Fattoum, Wael Imam, Mhd Yasser Mukhalalaty, Musab Murad, Faizah Ali Al Quobaili","doi":"10.18502/ijhoscr.v18i2.15376","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i2.15376","url":null,"abstract":"Background: Hemoglobinopathies are common inherited blood disorders in our Mediterranean area. The main structural hemoglobin variants are hemoglobin S and hemoglobin C, due to their prevalence. \u0000We conducted this retrospective study to investigate and characterize hemoglobin C patients referred to the National Center for Thalassemia and Genetic Counseling and the management of hemoglobin C disease in Damascus. \u0000Materials and Methods: The study included patients referred to the National Center for Thalassemia and Genetic Counseling in Damascus between 2000 and 2022 for hemoglobin C detection. Gender, age, geographical origin, hemoglobin electrophoresis profile, and blood transfusion were considered for hemoglobin C patient classification. Blood transfusion in five consecutive years and linear regression with hemoglobin S and C values were determined. \u0000Results: 30 (14 males and 16 females) out of 624 patients between 3 and 46 years old (mean ± SD: 17.3 ± 9.7 years) showed hemoglobin C disease. Only eight patients (one male and seven females) received blood transfusions, and the remaining patients (13 males and 9 females) did not receive any transfusion. Only one patient with 100% hemoglobin C was detected; 19 showed HbSC, and 10 had HbAC. There was a significant correlation between hemoglobin S and geographical origin (P-value=0). \u0000Conclusion: A Homozygote hemoglobin C patient has mild hemolytic anemia, whereas the hemoglobin C 100% patient has only a one-time blood transfusion (he was 17 years old) in our study. The inherited combination of hemoglobin C and S is less severe than hemoglobin S alone. There is a significant relationship between hemoglobin S and geographical origin (p-value=0).","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"23 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140663519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of Sarcopenia Identified by Sarc-Calf, Nutritional Status and Hand Grip Strength in Patients with Hematological Cancer 通过血液肿瘤患者的 Sarc-Calf、营养状况和手部握力识别肌少症风险

International journal of hematology-oncology and stem cell research Pub Date : 2024-04-21 DOI: 10.18502/ijhoscr.v18i2.15370

Lorraine Pires Avancini, Laís Freitas da Costa, Mariana de Souza Vieira, Vanusa Felício de Souza, Rayne de Almeida Marques, Jose Luiz Marques Rocha, G. Petarli, V. Guandalini

{"title":"Risk of Sarcopenia Identified by Sarc-Calf, Nutritional Status and Hand Grip Strength in Patients with Hematological Cancer","authors":"Lorraine Pires Avancini, Laís Freitas da Costa, Mariana de Souza Vieira, Vanusa Felício de Souza, Rayne de Almeida Marques, Jose Luiz Marques Rocha, G. Petarli, V. Guandalini","doi":"10.18502/ijhoscr.v18i2.15370","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i2.15370","url":null,"abstract":"Background: Hematological cancer patients are prone to the development of sarcopenia and impaired nutritional and functional status. SARC-CalF is a screening tool for the risk of sarcopenia that has shown good results in this population. This study aimed to identify the risk of sarcopenia by SARC-CalF and to verify its association with nutritional status and Hand Grip Strength (HGS) in patients with hematological cancer. \u0000Materials and Methods: Adult patients, of both sexes, with hematological cancer, and in outpatient care participated in the study. We measured the Hand Grip Strength of the Dominant Hand (HGSD) and the Adductor Pollicis Muscle Thickness of the Dominant Hand (APMTD). Moreover, we applied the Patient-Generated Subjective Global Assessment (PG-SGA) and SARC-CalF. Data were analyzed with SPSS® software, 22.0, with a significance level of 5.0%. \u0000Results: Fifty-one patients aged an average of 60.4 ± 15.1 years were evaluated. Of those, 58.8% were elderly, 51% female, and 80.4% declared themselves non-white. The predominant diagnosis was Mature B Lymphoid Cell Neoplasia (37.7%), and 60.8% of the patients had a diagnosis time of ≤ 3 years. PG-SGA revealed that 35.3% of the patients were malnourished; APMTD and HGSD revealed that 60.8% and 25.5% had reduced muscle strength, respectively. SARC-CalF exposed that 39.2% of the patients were at risk for sarcopenia. Significant associations were found between SARC-CalF and diagnosis time ≤ 3 years (p = 0.039), PG-SGA (p = 0.020), APMTD (p = 0.039) and HGSD (p = 0.002). After binary logistic regression adjusted for age and sex, the reduced HGSD remained associated with the risk of sarcopenia. \u0000Conclusion: SARC-CalF identified a risk of sarcopenia in 39.2% of patients. The reduced HGSD was associated with the risk of sarcopenia.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"102 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140678941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum Interleukin 6 (IL -6) as Prognostic Marker in Egyptian CLL patients 血清白细胞介素 6 (IL -6) 作为埃及 CLL 患者的预后指标

International journal of hematology-oncology and stem cell research Pub Date : 2024-04-21 DOI: 10.18502/ijhoscr.v18i2.15369

E. A. Hassan, E. Abdelhady, H. Abdelsamee, Mohamed Tarif Hamza sallam, M. El-Razzaz

{"title":"Serum Interleukin 6 (IL -6) as Prognostic Marker in Egyptian CLL patients","authors":"E. A. Hassan, E. Abdelhady, H. Abdelsamee, Mohamed Tarif Hamza sallam, M. El-Razzaz","doi":"10.18502/ijhoscr.v18i2.15369","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i2.15369","url":null,"abstract":"Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Currently, several biomarkers are being used as CLL prognosticators, including elevated protein levels, elevated RNA levels, gene mutations, and epigenetic changes. \u0000Materials and Methods: This study is a prospective study conducted on 55 patients newly diagnosed with CLL, serum IL-6 level was measured initially and after a 6-month treatment course. Correlation with the course of the disease and the known CLL prognostic parameters was done initially and after 6 months. \u0000Results: The initial serum IL-6 level in the patient group (pre-treatment) ranges from 36-91 pg/mL (median 57), and in the patient group (post-treatment) ranges from 1-32 pg/mL (median 2). Serum IL-6 level was positively correlated with WBC count, β2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes), and Binet and Rai staging systems. \u0000Conclusion: Serum IL-6 is a useful poor prognostic marker in newly diagnosed CLL patients; its prognostic value goes with the other known prognostic markers such as the BM lymphocyte count, ESR, and LDH.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"103 27","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140678845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0